aBLA Filing Intelligence & Biosimilar Opportunity

Niktimvo

Axatilimab-Csfr

Immunomodulators

Intravenous Infusion

Niktimvo is an IV antibody treatment for adults and children (≥ 40 kg) with chronic graft‑versus‑host disease whose condition worsened despite at least two prior therapies. It works by blocking CSF‑1R to calm overactive immune cells and reduce symptoms.

Approval Date

14-Aug-24

Data Exclusivity Expiry

14-Aug-28

Market Exclusivity Expiry

14-Aug-36

Commercial snapshot

Market performance & projections

Revenue ($M)

152

CAGR (%)

56.72%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

458

2027

647

2028

789

2029

917

2030

1,055

2031

1,143

2032

1,236

Molecule profile

Details & specifications

Molecule

Axatilimab-Csfr

Innovator

INCYTE CORPORATION

Dosage Form

Intravenous Infusion

Strength

50 mg/mL, 9 mg/0.18 mL and 22 mg/0.44 mL

Therapeutic Category

Immunomodulators

Usage

To treat chronic graft-versus-host disease (cGVHD)

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets